Ember Therapeutics Inc EMBT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.40
- Market Cap
- $370.75
- Volume/Avg
- 3,200 / 1,838
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ember Therapeutics Inc is engaged in the healthcare sector. It is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies. It looks to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- http://www.embertx.com
Valuation
|
Metric
|
EMBT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EMBT
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −2.26 |
Quick Ratio
EMBT
Profitability
|
Metric
|
EMBT
|
|---|---|
Return on Assets (Normalized) | −1,021.30% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
EMBT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jmfnvbry | Zwrzl | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jdgbxmnd | Yxvsxm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pnjrhkh | Sjwqmp | $99.5 Bil | |
MRNA
| Moderna Inc | Zplcfjqgj | Dzppv | $38.8 Bil | |
ARGX
| argenx SE ADR | Wjllcjjd | Dyxy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rkrympcjf | Ytcms | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bsrynmpgb | Zrkyjbd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tzlbkxjt | Fndzc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qtxghqdqht | Dkqhy | $12.5 Bil | |
INCY
| Incyte Corp | Hkkpffsb | Ybnxphb | $11.6 Bil |